AZN 240816 80.00C (AZN240816C80000) Stock Options, News & Quotes

3.85
+1.26+48.65%

15min DelayClose Aug 13 15:59 ET

3.85High3.07Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Ryand83

Aug 10 16:18

$LumiraDx (LMDXF.US)$ I think whatever $ROCHE HOLDING AG (RHHBY.US)$ intends to do is going to be massive. Owning 75% or more of the company float means at the bare minimum if this were say a 50B deal Roche would only essentially lose out maximum 10B. I'm just thinking to myself if the other pharmas $AstraZeneca (AZN.US)$ & the other one got a piece of this 🥧 too.

CHFANTA

Aug 1 09:54

$AstraZeneca (AZN.US)$ you can do better~

GraniteShares

Jul 25 12:37

AstraZeneca Earnings Report Q2 2024

AstraZeneca for the second quarter reported total revenue of $12.938 billion, which increased by 13% on a Year-on-Year (YoY) basis. Moreover, On a half-year basis, total Revenue was up by 18% YoY, which stood at $25.617 billion. The revenue growth was driven by an 18% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines.

On a segment basis, total revenue growth from Oncology, cardiovascular, renal and metabolism (CVRM), ...

Meltyy

Jul 25 03:45

$AstraZeneca (AZN.US)$
AdCom for IMFINZI (durvalumab) tomorrow 7/25 🗓️
» IMFINZI + platinum-containing chemo
» as Tx for non-small cell lung cancer (NSCLC)
Briefing docs for Thursday’s AdCom posted yesterday…
⚠️ FDA highlights concerns about Imfinzi for perioperative NSCLC:
» overtreatment risk
» uncertainty on treatment benefit
» inadequate trial design
» lack of overall survival benefit
» potential for unnecessary exposure
⏰ Meeting begins Thursday, 9 a.m. ET.

Meltyy

Jul 18 22:02

Check out PDUFA & AdCom left in July! 📅 👇

$AstraZeneca (AZN.US)$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom: 7/25/24 (sBLA)
$BeiGene (BGNE.US)$ : 🤔
⇨ TEVIMBRA (tislelizumab)
‣ Esophageal squamous-cell carcinomas (1L)
‣ PDUFA: July 2024 (sBLA)